Teva Pharmaceutical Industries Limited (TEVA) Goldman Sachs 47th Annual Global Healthcare Conference 2026 June 8, 2026 8:00 AM EDT
Company Participants
Richard Francis – President, CEO & Director
Conference Call Participants
Matthew Dellatorre – Goldman Sachs Group, Inc., Research Division
Presentation
Matthew Dellatorre
Goldman Sachs Group, Inc., Research Division
Okay. Great. Great. Well, good morning, everyone, and thank you for joining us. My name is Matt Dellatorre, and I’m a biopharma analyst here at Goldman Sachs. And we’re really excited to kick off the conference this morning with Teva Pharmaceutical, where I’m joined by Richard Francis, the company’s CEO.
Richard, thank you for being here.
Richard Francis
President, CEO & Director
My pleasure, Matt. Good to be here.
Question-and-Answer Session
Matthew Dellatorre
Goldman Sachs Group, Inc., Research Division
Maybe just to kind of kick us off, give us an overview of where Teva stands today, including your core franchises, both branded and generic, your key pipeline priorities and just how you’re thinking about the outlook and strategy for the company over the coming years.
Richard Francis
President, CEO & Director
Well, thanks for that question. So the outlook and the strategy for the next coming years is more of the same. So we sort of go back to the foundations of Pivot to Growth, the 4 pillars: deliver on our growth engines, step up innovation, create generics powerhouse and focus the business, which is all about capital allocation. And we’ve been executing that religiously for 3.5 years, and I think you’ve seen the results of that.
But specifically, I think the way for people to think about it is when you talk about the branded business, if you think about delivering our growth engines, we have, I think, put AUSTEDO on a clear path to more than $3 billion of peak sales, which I think was something
